Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 8 of 16 for:    CCL22

Investigation of Efficacy of Secukinumab in Patients With Moderate to Serve Atopic Dermatitis (Secu_in_AD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03568136
Recruitment Status : Recruiting
First Posted : June 25, 2018
Last Update Posted : November 28, 2018
Sponsor:
Collaborator:
Novartis Pharmaceuticals
Information provided by (Responsible Party):
GWT-TUD GmbH

Brief Summary:
The overall aim of this study is to assess the effects of a new treatment called Secukinumab in adults suffering from moderate to severe atopic dermatitis. Furthermore, the study shall support the extension of the approval for Secukinumab from psoriasis to atopic dermatitis. The effectiveness of Secukinumab is determined on the reduction of the eczema score EASI 50 (Eczema Area and Severity Index, a tool to measure the severity of atopic dermatitis) at week 4.

Condition or disease Intervention/treatment Phase
Dermatitis, Atopic Eczema, Atopic Neurodermatitis, Atopic Drug: Secukinumab 300 mg Drug: Placebo Phase 2

Detailed Description:

Secukinumab is a humanized anti-IL-17A monoclonal antibody. Since Secukinumab is well established in the therapy of psoriasis with a highly favorable benefit to risk ration and IL-17 has been described in atopic dermatitis this study aims to investigate the effects of anti-IL-17 in atopic dermatitis.

This is a randomized, placebo-controlled, multicenter, double-blinded study to evaluate the efficacy and safety of subcutaneous Secukinumab compared to placebo in 45 adults with atopic dermatitis.

The study consists of 3 periods: a screening period of at least -28 days and up to -35 days, and a treatment period of 16 weeks and a follow-up period of additional 8 weeks. During the screening period eligibility of the patients is confirmed. Eligible patients are randomized 2:1 to treatment arm A or B at Day -20 during the randomization visit. Secukinumab (Cosentyx®) will be used according to the official label and SmPC (Summary of Product Characteristics). Patients in treatment arm A receive 300 mg Secukinumab administered as 2 subcutaneous injections of 150 mg (i.e. 2x 150 mg) at baseline day 1 and week 1, 2, 3, 4, 8, 12 and injections with placebo at week 5, 6, 7 and 16. For assessments of the study endpoints were followed up visits at week 20 and 24. Placebo will be administered as 2 subcutaneous injections. Patients in treatment arm B receive placebo until visit 3 (week 3) and will switch to Secukinumab 300 mg s.c. up from visit 4 (week 4), visit 5, 6, 7, 8, 12 and16. For assessments of the study endpoints were followed up visits at week 20 and 24.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 45 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Placebo-controlled, Double-blind Study to Scrutinize the Efficacy of Secukinumab in Patients With Moderate to Severe Atopic Dermatitis
Actual Study Start Date : September 18, 2018
Estimated Primary Completion Date : September 2019
Estimated Study Completion Date : July 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eczema
Drug Information available for: Secukinumab

Arm Intervention/treatment
Experimental: Treatment Arm A
Patients in treatment arm A receive 300 mg Secukinumab administered as 2 subcutaneous injections of 150 mg (i.e. 2x 150 mg) at baseline day 1 and week 1, 2, 3, 4, 8, 12 and injections with placebo at week 5, 6, 7 and 16. For assessments of the study endpoints were followed up visits at week 20 and 24. Placebo will be administered as 2 subcutaneous injections.
Drug: Secukinumab 300 mg
Solution for injection in pre-filled syringe
Other Name: COSENTYX ®

Drug: Placebo
Solution for injection in pre-filled syringe
Other Name: Placebo (for Secukinumab)

Placebo Comparator: Treatment Arm B
Patients in treatment arm B receive placebo until visit 3 (week 3) and will switch to Secukinumab 300 mg s.c. up from visit 4 (week 4), visit 5, 6, 7, 8, 12 and16. For assessments of the study endpoints were followed up visits at week 20 and 24.
Drug: Secukinumab 300 mg
Solution for injection in pre-filled syringe
Other Name: COSENTYX ®

Drug: Placebo
Solution for injection in pre-filled syringe
Other Name: Placebo (for Secukinumab)




Primary Outcome Measures :
  1. Reduction in EASI [ Time Frame: week 4 (visit 4) ]
    Proportion of patients with a reduction of the eczema score EASI of at least 50%. The proportions are then compared between study arms.


Secondary Outcome Measures :
  1. Reduction of EASI [ Time Frame: baseline (day 1, visit 0) and End of Trial (Arm A week 12 / Arm B week 16) ]
    To compare the proportions of patients with a reduction of the eczema score EASI 50.

  2. Reduction of EASI [ Time Frame: Arm A week 12 / Arm B week 16 ]
    To compare the number of patients with a reduction of the eczema score EASI 50.

  3. Reduction in SCORAD (Scoring atopic dermatitis) [ Time Frame: day 1, week 4 and Arm A week 12 / Arm B week 16 ]
    The number of patients with a reduction of 50 % in SCORAD index.

  4. Change in pruritus score (Visual Analogue Scale) [ Time Frame: day 1, week 4 and Arm A week 12 / Arm B week 16 ]
    To compare the proportion of patients with change in pruritus score (VAS) by 50 %.

  5. Change in IGA Score (5-point Investigator's Global Assessment) [ Time Frame: Arm A week 12 / Arm B week 16 ]
    To compare the proportion of patients who achieve a score of "clear-0" or "almost clear-1" in the static IGA score compared to baseline.

  6. Serum biomarkers CCL17 and CCL22 [ Time Frame: day 1, week 4 and Arm A week 12 / Arm B week 16 ]
    To compare the serum biomarkers CCL17 and CCL22.

  7. Increase in DLQI (Dermatology Life Quality Index) [ Time Frame: day 1, week 4 and Arm A week 12 / Arm B week 16 ]
    To compare the proportion of patients achieving increase in DLQI by 30 %.

  8. Consumption of topical methylprednisolone aceponate [ Time Frame: day 1, week 4 and Arm A week 12 / Arm B week 16 ]
    To evaluate the quantification of the consumption of topical methylprednisolone aceponate 0.1% in gram.

  9. Serious and non-serious adverse drug reactions [ Time Frame: treatment phase (day 1 up to week 16), follow-up phase (week 20, week 24) ]
    To observe any serious adverse drug reactions and non-serious adverse drug reactions.

  10. Gender distribution in patients with atopic dermatitis [ Time Frame: study arm A week 4 and both study arms week 16 ]
    Subgroup analyses will be performed to compare the effects of treatment with Secukinumab in male and female patients. Therefore, the recorded gender data will be used and separately analyzed for the above mentioned primary and secondary endpoints.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Atopic dermatitis (intrinsic disease without IgE mediated sensitization defined by negative history and negative SX-1 CAP FEIA) or extrinsic disease defined by positive history and / or positive SX-1 CAP FEIA),
  2. SCORAD index score ≥ 25,
  3. EASI ≥ 16,
  4. Male and female patients at the age of 18 to 85 years,
  5. Signed Informed Consent,
  6. Subjects must be able to understand and communicate with the investigator and comply with the requirements of the study and must give a written, signed and dated informed consent before any study related activity is performed,
  7. Subject is judged to be in good general health as determined by the principal investigator based upon the results of medical history, laboratory profile, and physical examination,
  8. Patients with stable chronic asthma, treated with inhaled corticosteroids, will be allowed to participate.

Exclusion Criteria:

  1. Other inflammatory skin disease than atopic dermatitis,
  2. Use of cyclosporine, azathioprine, mycophenolate [wash-out period of 4 weeks]; Phototherapy (PUVA, NB-UVB, UVA1; [wash-out period of 2 weeks]),
  3. Subjects expected to be exposed to an undue safety risk if participating in the trial including chronic infections,
  4. Contraindications of Secukinumab by label (i.e. approval for the treatment of psoriasis in the EU - refer to point 14 - 16 at the bottom of this section),
  5. Current severe progressive or uncontrolled disease which in the judgment of the investigator renders the subject unsuitable for the trial,
  6. Plans for administration of live vaccines during the study period,
  7. Chronic infection,
  8. Patients with instable chronic asthma,
  9. Patients with Crohn's disease,
  10. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (>10 mIU/mL),
  11. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unwilling to use effective contraception during the study and for 20 weeks after stopping treatment. Effective contraception is defined as either:

    1. Barrier method: Condom or occlusive cap (diaphragm or cervical/vault caps) with spermicide (where available). Spermicides alone are not a barrier method of contraception and should not be used alone,
    2. The following methods are considered more effective than the barrier method and are also acceptable:
    3. Total abstinence: When this is in line with the preferred and usual lifestyle of the subject (Periodic abstinence [e.g. calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception),
    4. Female sterilization: have had a surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment,
    5. Male partner sterilization (at least 6 months prior to screening). For female subjects on the study, the vasectomized male partner should be the sole partner for that subject,
    6. Use of established oral, injected or implanted hormonal methods of contraception, intrauterine device (IUD) or intrauterine system (IUS) NOTE: Women are considered post-menopausal and not of child bearing potential if they have had:

    i. 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or • six months of spontaneous amenorrhea with serum FSH levels >40 mIU/mL

    Or

    ii. Surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.

  12. History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening,
  13. Positive with hepatitis B surface antigen (HBsAg) or hepatitis C antibody at the screening visit (a report ≤ 6 months is also accepted),
  14. History of alcohol or drug abuse within 1 year of the screening visit,
  15. Planned major surgical procedure during the patient's participation in this study,
  16. Hypersensitivity against Secukinumab,
  17. Active or reactive tuberculosis,
  18. Participation in other clinical studies.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03568136


Contacts
Layout table for location contacts
Contact: Carmen Weigt, Dr : +49 (0) 351 25933 ext 172 carmen.weigt@gwtonline.de

Locations
Layout table for location information
Germany
Carl Gustav Carus University Hospital, Department of Dermatology Recruiting
Dresden, Germany, 01307
SRH Wald-Klinikum Gera, Center for Clinical Studies Recruiting
Gera, Germany, 07548
Hannover Medical School, Department for Dermatology, Allergy and Venereology Recruiting
Hannover, Germany, 30625
Sponsors and Collaborators
GWT-TUD GmbH
Novartis Pharmaceuticals
Investigators
Layout table for investigator information
Principal Investigator: Stefan Beissert, Prof. Dr.

Layout table for additonal information
Responsible Party: GWT-TUD GmbH
ClinicalTrials.gov Identifier: NCT03568136     History of Changes
Other Study ID Numbers: Secu_Trial
2016-005181-57 ( EudraCT Number )
First Posted: June 25, 2018    Key Record Dates
Last Update Posted: November 28, 2018
Last Verified: November 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by GWT-TUD GmbH:
neurodermatitis
moderate to severe inflammatory reaction of the skin
Skin and Connective Tissue Diseases

Additional relevant MeSH terms:
Layout table for MeSH terms
Dermatitis, Atopic
Dermatitis
Eczema
Neurodermatitis
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs